Miocamycin is a macrolide antibiotic. Holliday SM, Faulds D (October 1993). "Miocamycin. A review of its antimicrobial activity ...
Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ... Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ... Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ... Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ...
miocamycin. TAO. troleandomycin. EM. erythromycin. CAM. clarithromycin. MDM. midecamycin. DMSO. dimethyl sulfoxide. ... In this study, the possibility of MI complex formation by miocamycin (MOM) was assessed first. CYP contents and activities in ... Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ... Studies on the Cytochrome P450 (CYP)-Mediated Metabolic Properties of Miocamycin: Evaluation of the Possibility of a Metabolic ...
Miocamycin. Cytochrome P450 3A4. enzyme. DB13338. Flurithromycin. Cytochrome P450 3A4. enzyme. DB13409. Rokitamycin. Cytochrome ...
This updated edition in the long standing series provides the latest information on many individual drugs, including the most complete coverage of their adverse reactions and interactions.
Miocamycin - Meiji Seika Kaisha. Miotin - Thai Meiji Pharmaceutical; Nomura Trading; Thien Thao Pharmaceutical. Momicine - ...
A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing. ...
Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) ... High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of ...
Midecamycin acetate 特集II Toxicological studies on a new macrolide antibiotic, midecamycin acetate(miocamycin)Part VI-1. Acute ... Midecamycin acetate 特集II Toxicological studies on a new macrolide antibiotic, midecamycin acetate(miocamycin)Part VI-2. Acute ... Midecamycin acetate 特集II Toxicological studies on a new macrolide antibiotic, midecamycin acetate(miocamycin)Part IV-1. ... Midecamycin acetate 特集II Toxicological studies on a new macrolide antibiotic, midecamycin acetate(miocamycin)Part IV-2. ...
Miocamycin - Rokitamycin - Dirithromycin - Flurithromycin - Telithromycin. ...
... observations on phagocytosis and bacterial killing in the presence of miocamycin. Chemioterapia, 7(2), 89-95. ...
Pozzi E. Clinical efficacy of dirithromycin versus miocamycin in the treatment of acute bronchitis or acute exacerbations of ...
Trademarks: Miocamycin (Meiji). Molecular Formula: C45H71NO17. Molecular Weight: 898.04 ...
Certain 16-membered macrolides are also available in a few countries (spiramycin, josamycin, midecamycin, and miocamycin) or ...
... miocamycin MeSH D09.408.477.550 - natamycin MeSH D09.408.477.575 - nystatin MeSH D09.408.477.600 - oleandomycin MeSH D09.408. ...
... and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. J. Antimicrob. Chemother. 51, 333-337PubMedCrossRef ... Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of ...
Observations on phagocytosis and bacterial killing in the presence of miocamycin. Capelli, A., Capelli, O., Azzolini, L., ...
... miocamycin, rokitamycin, andazithromycin, and swinolide A; fluoroquinolones such as ciprofloxacin, ofloxacin, levofloxacin, ...
Miocamycin Susc Islt 3 LOINC_Long_Common_Name LOINC Long Common Name Miocamycin [Susceptibility] ...
Miocamycin Susc Islt Code System Concept Status. Published. Code System Preferred Concept Name. Miocamycin [Susceptibility]. ...
... miocamycin and rokitamycin and derivatives thereof, such as ketolides (e. g., 3-ketone), lactams (e. g., 8a-or 9a-lactams) and ...
Puromycin is an aminonucleoside antibiotic, derived from the Streptomyces alboniger bacterium,[1] that causes premature chain termination during translation taking place in the ribosome. Part of the molecule resembles the 3 end of the aminoacylated tRNA. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release.[2] The exact mechanism of action is unknown at this time but the 3 position contains an amide linkage instead of the normal ester linkage of tRNA. That makes the molecule much more resistant to hydrolysis and stops the ribosome. Puromycin is selective for either prokaryotes or eukaryotes. Also of note, puromycin is critical in mRNA display. In this reaction, a puromycin molecule is chemically attached to the end of an mRNA template, which is then translated into protein. The
First isolated from the Streptomyces fradiae and Streptomyces albogriseus in 1949 (NBRC 12773).[12] Neomycin is a mixture of neomycin B (framycetin); and its epimer neomycin C, the latter component accounting for some 5-15% of the mixture. It is a basic compound that is most active with an alkaline reaction.[2] It is also a thermostable compound that is soluble in water while insoluble in organic solvents.[2] Neomycin has good activity against Gram-positive and Gram-negative bacteria, but is very ototoxic. Its use is thus restricted to oral treatment of intestinal infections.[13] Neomycin B is composed of four linked parts: D-neosamine, 2-deoxystreptamine (2-DOS), D-ribose, and L-neosamine. Neomycin A, also called neamine, contains D-neosamine and 2-deoxystreptamine. ...
Erythromycin is metabolized by enzymes of the cytochrome P450 system, in particular, by isozymes of the CYP3A superfamily, CYP3A (Hunt et al., 1992). The activity of the CYP3A enzymes can be induced or inhibited by certain drugs (e.g. dexamethasone) which can cause it to affect the metabolism of many different drugs, e.g. erythromycin. If other CYP3A substrates - drugs that are broken down by CYP3A - such as simvastatin (Zocor), lovastatin (Mevacor), or atorvastatin (Lipitor)-are taken concomitantly with erythromycin, levels of the substrates will increase, often causing adverse effects. A noted drug interaction involves erythromycin and simvastatin, resulting in increased simvastatin levels and the potential for rhabdomyolysis. Another group of CYP3A4 substrates are drugs used for migraine such as ergotamine and dihydroergotamine; their adverse effects may be more pronounced if erythromycin is associated.[11] Earlier case reports on sudden death prompted a study on a large cohort that confirmed ...
神経・筋遮断作用:(稀であるが)神経筋遮断作用(およびこれによる無呼吸)を呈する。遮断作用はネオマイシンが一番強く、カナマイシン、アミカシン、ゲンタマイシン、トブラマイシンがこれ
... , sold under brand names Garamycin among others, is an antibiotic used to treat several types of bacterial infections1 This may include bone infe
Miocamycin - Preferred Concept UI. M0023981. Scope note. A macrolide antibiotic that has a wide antimicrobial spectrum and is ... Miocamycin Entry term(s). 9,3 Di O Acetylmidecamycin 9,3 Diacetylmidecamycin 9,3-Di-O-Acetylmidecamycin 9,3- ...
... or miocamycin? or moxalactam? or mupirocin? or mycobacillin? or nafcillin? or natamycin? or nebramycin? or neomycin? or ...
roxithromycin and miocamycin. Eighty eight strains came from skin of soft tissues, 19 from surgical wounds, 18 from invasive ... All strains were susceptible to penicillin, ampicillin, cefazolin, cefuroxime, roxithromycin and miocamycin. Ninety nine ...
miocamycin dosage for amoxicillin. The shape and size of the sodium alginate microparticles could be tuned by adjusting the ...